Overview on Multi-Regional Clinical Trials in Japan from Sponsor’s Point of View

- Advantages & Issues in MRCT involving China-

Vice-chairperson of Regulatory Affairs Committee, JPMA
Senior Director, Regulatory Affairs Dept, Pharmaceutical Development Div.
Takeda Pharmaceutical Company Ltd.

Masaaki Kuwahara, Ph.D.
1. Introduction

2. Multi-Regional Clinical Trials (MRCT) from sponsor’s point of view

   Findings from questionnaire to 59 JPMA member companies conducted in 2010 and 2011

3. Advantages of MRCT involving China and successful cases
   - In general
   - Approval cases study

4. Issues in MRCT involving China
   - Issues in regulations and operations
Increasing Global and Asian Studies

Source: PMDA's publication
Agenda

1. Introduction
2. Multi-Regional Clinical Trials (MRCT) from sponsor’s point of view
   Findings from questionnaire to 59 JPMA member companies conducted in 2010 and 2011
3. Advantages of MRCT involving China and successful cases
   ◆ In general
   ◆ Approval cases study
4. Issues in MRCT involving China
   ◆ Issues in regulations and operations
Number of projects of domestic and global development by each company

Data of 13 companies without development project excluded

List the companies in order of the No of projects
Development Phase of Global/Asian Studies

Global studies
- P1 study: 20 (6%)
- POC study: 5 (2%)
- PII study: 72 (22%)
- PIII study: 223 (70%)

Asian studies
- P1 study: 10 (13%)
- POC study: 1 (1%)
- PII study: 12 (16%)
- PIII study: 53 (70%)

Legend:
- Blue: P1 study
- Red: POC study
- Green: PII study
- Purple: PIII study
Areas where MRCT is always considered

- Basically all the areas 10 companies
- Oncology 8 companies / CV 7 companies / CNS 6 companies
- Others (Anti-infectives, anti-inflammatory, Urology, etc)
- Orphan drugs 3 companies

Reasons: Development efficiency (number of cases, cost, speed), launch accuracy, company strategy

Conditions: No marked ethnic difference, no time restriction = good timing, similar evaluation criteria between Japan and overseas, large scale (long term) study
Rapid information sharing and safety security among multiple countries can be assured.

Conduct in Japan is difficult due to manufacture of investigational drug, etc.

There is no time for preparation/conduct of PI study in Japan.

It is essential to general PK data of the race in the relevant country/region

Issue of cost in the stage where POC is yet to be determined

Time required for procedures for clinical trial start

It is more efficient to conduct the study at one site in one region
Factors for Participating in MRCT in Each Development Stage – POC Study

Requirements/Factors for participating

* Diseases specific to Japan (Asia)

Factors for not participating

* Issue of cost in the stage where POC is yet to be determined
* Time required for procedures for clinical trial start
* It is more efficient to conduct the study at one site in one region because POC study is usually conducted in a small number of subjects and it is difficult to examine the ethnic difference in the study to determine product profile
Factors for Participating in MRCT in Each Development Stage – PII, III Studies

Requirements/Factors for participating

* Timing is suitable for participation.
* Launch accuracy, development speed and cost exceed the risk.
* No ethnic difference suggested in PK (whether difference in doses for approved drugs in the same class exists or not)
* Assurance of safety of the drug in higher doses
* Feasibility of the study conduct with unified protocol (evaluation method, investigational drug, medical practices) in Japan Number of Japanese patients with the disease
* Agreeability of the protocol with the regulators in terms of study design such as dosage, concomitant drugs, control drug, scale, duration and endpoints.
* Efficiency of patient recruitment – Particularly PIII studies
When to Plan Asian Studies

- No response: 6
- Not participate in Asian studies: 2
- Others: 14
- For patient recruitment: 27
- Could not participate in global study: 17
- Not in time for global study: 17
- Study in disease popular in Asia: 32

Number of companies
1. Introduction

2. Multi-Regional Clinical Trials (MRCT) from sponsor’s point of view
   Findings from questionnaire to 59 JPMA member companies conducted in 2010 and 2011

3. Advantages of MRCT involving China and successful cases
   ◆ In general
   ◆ Approval cases study

4. Issues in MRCT involving China
   ◆ Issues in regulations and operations
Advantages of MRCT Involving China

**Strategic point of view**

* Cancer/hepatitis of similar disease background
* No ethnic difference
* No cultural difference
  - Share similar views on some issues
* Low cost, fast recruitment

**Operational point of view**

* Timely Communication as no time different
  - Quick action for any issue raised
* Sufficient support by Medical background staff and scientific and monitoring background staff to local monitoring team
<table>
<thead>
<tr>
<th>Name of Drug</th>
<th>Indication</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tolterodine</td>
<td>Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency</td>
<td>Apr.2006</td>
</tr>
<tr>
<td>Insulin glulisine</td>
<td>Diabetes mellitus</td>
<td>Apr.2009</td>
</tr>
<tr>
<td>Peramivir</td>
<td>Type A and Type B Influenza virus infection</td>
<td>Jan.2010</td>
</tr>
<tr>
<td>Laninamivir</td>
<td>Type A and Type B Influenza virus infection</td>
<td>Sep.2010</td>
</tr>
<tr>
<td>Edoxaban</td>
<td>Prevention of venous thromboembolism after major orthopedic surgery</td>
<td>Apr.2011</td>
</tr>
<tr>
<td>Indacaterol</td>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>Jul. 2011</td>
</tr>
<tr>
<td>Gefitinib</td>
<td>EGFR mutation-positive inoperable or relapsed non-small cell lung cancer</td>
<td>Nov.2011</td>
</tr>
<tr>
<td>Aripiprazole</td>
<td>Manic symptoms associated with bipolar disorder</td>
<td>Jan.2012</td>
</tr>
</tbody>
</table>

*: Not approved in USA
Japanese data
- Phase I (healthy male subjects)
- Phase II (influenzae virus infected patients)
- Phase III
  - Single dose Asian study (influenzae virus infected patients)
  - Single and repeated doses study (at risk patients infected with influenzae virus)

Overseas data
- Phase I (healthy male subjects, patients with renal failure, the elderly)
Reasons for adopting Asian study

- Seasonal disease ⇒ Completion of the clinical study in one season was challenged
- No marked difference between races
- Reduction in cost (Estimation: 30-60% reduction)

Reasons for selecting Korea and Taiwan

- Clinical stats of influenza is similar to that in Japan
- Study initiation in short time (seasonal disease)
  - IND period considered
- Number of collectable cases
  - Hundreds of cases expected to be collected in one season
Plasma concentrations of peramivir (actual measurements) in influenza virus infected patients and time plotted mean plasma concentrations in population of each region

○: Japan  □: Korea  △: Taiwan

Solid line: Mean plasma concentration simulation curve in Japanese population
Break line: Mean plasma concentration simulation curve in Korean population
Dotted line: Mean plasma concentration simulation curve in Taiwanese population
## Summary and Results of Asian Study

<table>
<thead>
<tr>
<th>Country</th>
<th>Japan</th>
<th>Korea</th>
<th>Taiwan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target number of cases</td>
<td>1,050 (350 x 3 arms)</td>
<td>550</td>
<td>250</td>
</tr>
<tr>
<td>Registered number of cases</td>
<td>743</td>
<td>106</td>
<td>250</td>
</tr>
</tbody>
</table>

### Factor for ↑
- Met seasonal epidemic
- GP sites
- RAT is common
- Phase 2 study

### Factor for ↓
- Lost the first peak
- Less GP referral
- RAT is uncommon

### Influenza Standard Therapy
- Anti-influenza drug

**RAT:** Rapid Antigen Test
Weekly Patient Enrollment

- TAIWAN
- KOREA
- JAPAN

No. of Patient

<table>
<thead>
<tr>
<th>Month</th>
<th>TAIWAN</th>
<th>KOREA</th>
<th>JAPAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nov</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan</td>
<td>0</td>
<td>100</td>
<td>200</td>
</tr>
<tr>
<td>Feb</td>
<td>300</td>
<td>400</td>
<td>500</td>
</tr>
<tr>
<td>Mar</td>
<td>600</td>
<td>700</td>
<td>800</td>
</tr>
<tr>
<td>Apr</td>
<td>900</td>
<td>1000</td>
<td>1100</td>
</tr>
</tbody>
</table>

Year

- 2008
- 2009
• Placebo controlled double blind comparison study (Asian study)
• Double blind long-term continuation study (Asian study)
• Non blind long-term continuation study with concomitant use of mood-stabilizing drug (Asian study)
• Non blind long-term continuation study with concomitant use of mood-stabilizing drug (Japan)

Overseas clinical data used as “referential data”
Case study 2  **Aripiprazole (bipolar disorder)**

Number of Cases for Efficacy Evaluation in Asian Pivotal Study

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Aripiprazole group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>247</td>
<td>122</td>
<td>125</td>
</tr>
<tr>
<td><strong>Japan</strong></td>
<td>79 (32.0%)</td>
<td>39</td>
<td>40</td>
</tr>
<tr>
<td><strong>China</strong></td>
<td>56 (23.9%)</td>
<td>28</td>
<td>28</td>
</tr>
<tr>
<td><strong>Taiwan</strong></td>
<td>35 (14.2%)</td>
<td>17</td>
<td>18</td>
</tr>
<tr>
<td><strong>Indonesia</strong></td>
<td>15 (6.1%)</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td><strong>Malaysia</strong></td>
<td>25 (10.1%)</td>
<td>12</td>
<td>13</td>
</tr>
<tr>
<td><strong>Philippines</strong></td>
<td>37 (15.0%)</td>
<td>19</td>
<td>18</td>
</tr>
</tbody>
</table>

Source: Review Report

- Asian study led by Japan was conducted in neurophychiatric area where ethnic difference is said to be relatively large.
- For drugs like aripiprazole already approved in the West, conduct of such Asian study is beneficial in reduction in development time.
1. Introduction
2. Multi-Regional Clinical Trials (MRCT) from sponsor’s point of view
   Findings from questionnaire to 59 JPMA member companies conducted in 2010 and 2011
3. Advantages of MRCT involving China and successful cases
   ◆ In general
   ◆ Approval cases study
4. Issues in MRCT involving China
   ◆ Issues in regulations and operations
Issues in MRCT Involving China 1 - In perspective of regulations and operations -

- Establishment of clinical trial/development consultation system
- Acceleration of issue of therapeutic guidelines in China (diagnosis, treatment, clinical studies)
- Reduction in CTA review time by differentiating IND (CTA) review system and NDA review system in China (submission dossier, review process and timeline) (difficult to progress in parallel in case of global study)
  - Particularly, simplification of CMC dossiers and abolishment of submission of investigational drug sample in CTA
- Increase in Chinese CDE reviewers
In MRCT, investigational drug should be the drug registered in China or overseas or in PII or PIII stage. Acceptance of participation of China to FIH studies is requested.

Only the drugs approved in China can be used as the control drug.

Acceleration of EC, investigator & study nurse (coordinator) training in China

Acceptance of dossiers in foreign language by Chinese agency
Thank you!